<DOC>
	<DOCNO>NCT00219102</DOCNO>
	<brief_summary>To evaluate blood pressure lower effect safety aliskiren use combination valsartan/hydrochlorothiazide diabetic patient essential hypertension , adequately responsive combination valsartan hydrochlorothiazide</brief_summary>
	<brief_title>A Clinical Study Evaluate Safety &amp; Efficacy Combination Aliskiren , Valsartan &amp; Hydrochlorothiazide Diabetic Hypertensive Nonresponder Patients</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Inclusion Criteria Patients essential hypertension Patients document diagnosis Type 1 Type 2 diabetes mellitus . Patients eligible able participate study Exclusion Criteria Severe hypertension Uncontrolled diabetes type I II History evidence secondary form hypertension History Hypertensive encephalopathy cerebrovascular accident . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Hypertension ,</keyword>
	<keyword>diabetes ,</keyword>
	<keyword>aliskiren ,</keyword>
	<keyword>blood pressure ,</keyword>
	<keyword>valsartan ,</keyword>
	<keyword>hydrochlorothiazide</keyword>
</DOC>